Keywords: abraxis, study, nab-docetaxel, prostate, breast, cancer, bioscience

Abraxis to study nab-docetaxel in prostate and breast cancer

Article | 02 April 2007

Print This

Abraxis BioScience, an integrated, global, USA-based biopharmaceutical company, says that it will begin patient enrollment into a Phase I/II ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in